Rezetecan is a topoisomerase I inhibitor derived from exatecan, functioning as a potent cytotoxic payload in antibody-drug conjugates designed for the treatment of various cancers. By stabilizing topoisomerase… Read more
Rezetecan is a topoisomerase I inhibitor derived from exatecan, functioning as a potent cytotoxic payload in antibody-drug conjugates designed for the treatment of various cancers. By stabilizing topoisomerase I-DNA complexes, it inhibits DNA replication and induces apoptosis in rapidly dividing tumor cells. In pharmaceutical research and development, maintaining the efficacy and safety of such complex therapeutic agents requires precise analytical monitoring. Laboratories rely on high-quality reference standards, along with characterized impurities, metabolites, and stable isotope labelled compounds, to conduct accurate impurity profiling, method validation, and routine quality control. These materials enable researchers to detect and quantify trace-level degradants and transformation products throughout the manufacturing and stability testing processes, ensuring the integrity and consistency of the final drug product in both clinical and preclinical applications.